The efficacy and safety of a nicotine conjugate vaccine (NicVAX(®)) or placebo co-administered with varenicline (Champix(®)) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial

BACKGROUND: A potential new treatment in smoking cessation and relapse prevention is nicotine vaccination which is based on active immunization against the nicotine molecule. This immunization will elicit the immune system to produce nicotine-specific antibodies that sequester nicotine in the blood...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Hoogsteder, Philippe HJ, Kotz, Daniel, van Spiegel, Paul I, Viechtbauer, Wolfgang, Brauer, Ruth, Kessler, Paul D, Kalnik, Matthew W, Fahim, Raafat EF, van Schayck, Onno CP
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2012
Sujets:
Study Protocol
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3547752/
https://ncbi.nlm.nih.gov/pubmed/23216646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2458-12-1052
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires